MyFinsight
Home
Compare
About
Recent SEC Filings
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
Sensei Biotherapeutics, Inc. (SNSE)
Sensei Biotherapeutics, Inc. (SNSE)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Cash Flow Overview
Change in Cash
$143,657K
Free Cash flow
-$10,739K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of series...
Acquired in-process research and...
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Net loss
Purchases of short-term investme...
Issuance costs from the private ...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-170,236
-4,717
-4,568
-11,800
Stock-based compensation expense
12,898
295
254
725
Depreciation and amortization
29
30
30
62
Accretion on marketable securities
-83
-115
-142
-442
Impairment of financing right-of-use asset assets
-
0
-
-
Impairment of equipment
-
0
-
-
Non-cash lease expense
381
374
366
770
Amortization of financing lease right-of-use assets
1
4
4
9
Acquired in-process research and development from the acquisition of faeth therapeutics
-132,957
-
-
-
Gain on asset disposal
21
-
-1
-20
Prepaid expenses
-10,744
-266
-331
354
Other assets
-442
-178
126
-28
Accounts payable and accrued liabilities
-104
77
269
-113
Compensation and employee benefits
2,645
164
381
-1,107
Operating lease liabilities
-407
-399
-386
-801
Other liabilities
-
0
0
-
Net cash used in operating activities
-10,733
-3,864
-3,586
-13,003
Purchases of property and equipment
6
0
0
16
Purchases of short-term investments
43,894
6,522
9,847
8,786
Maturities of short-term investments
6,000
8,603
11,590
24,500
Proceeds from sale of property and equipment
0
0
0
250
Net cash assumed in the acquisition of faeth therapeutics
-6,464
-
-
-
Net cash (used in) provided by investing activities
-31,436
2,081
1,743
15,948
Principal payments for financing leases
62
113
152
525
Proceeds from issuance of series b redeemable convertible preferred stock
200,000
-
-
-
Proceeds from the sale of financing lease assets
-
0
0
142
Issuance costs from the private placement issuance of series b redeemable convertible preferred stock
15,145
-
-
-
Payment of employee restricted stock tax withholdings
0
0
0
3
Employee stock purchase plan proceeds
-
0
0
5
Cash in lieu of fractional shares for reverse stock split
-
0
0
1
Exercise of options into common stock
1,033
2
-
-
Net cash provided by (used in) financing activities
185,826
-111
-152
-382
Net increase (decrease) in cash and cash equivalents
143,657
-1,894
-1,995
2,563
Cash and cash equivalents at beginning of period
8,668
10,562
9,994
-
Cash and cash equivalents at the end of period
152,325
8,668
10,562
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
SNSE Cash Flow Sankey Diagram
Sankey diagram visualizing SNSE cash flow for the period
Proceeds from issuance of
series b redeemable...
$200,000K
Exercise of options into
common stock
$1,033K
Net cash provided by
(used in) financing...
$185,826K
Canceled cashflow
$15,207K
Net increase
(decrease) in cash and cash...
$143,657K
Canceled cashflow
$42,169K
Issuance costs from the
private placement...
$15,145K
Principal payments for
financing leases
$62K
Net cash assumed in
the acquisition of...
-$6,464K
Maturities of short-term
investments
$6,000K
Acquired in-process
research and development...
-$132,957K
Stock-based compensation
expense
$12,898K
Prepaid expenses
-$10,744K
Compensation and employee
benefits
$2,645K
Other assets
-$442K
Non-cash lease expense
$381K
Depreciation and
amortization
$29K
Amortization of financing
lease right-of-use...
$1K
Net cash (used in)
provided by investing...
-$31,436K
Net cash used in
operating activities
-$10,733K
Canceled cashflow
$12,464K
Canceled cashflow
$160,097K
Purchases of short-term
investments
$43,894K
Net loss
-$170,236K
Purchases of property and
equipment
$6K
Operating lease
liabilities
-$407K
Accounts payable and
accrued liabilities
-$104K
Accretion on marketable
securities
-$83K
Buy us a coffee